2000 · 27 citations · 3 references
PharmacyInternal MedicinePharmacotherapyAntimicrobial PharmacotherapyComparative Effectiveness ResearchPulmonologyAcute Exacerbation ManagementRespiratory DiseaseRespiratory MedicineAcute Bronchitis ManagementAcute Exacerbation TreatmentChronic Bronchitis TreatmentMedication-related Adverse EventsOral Antibiotic TherapyOutcome MeasuresPulmonary ExacerbationsSymptom Relief Therapy
• Objective: To compare the efficacy, safety, and patientreported effectiveness of short-course moxifloxacin versus azithromycin for the management of acute exacerbation of chronic bronchitis (AECB) in a primary care setting. • Design: Prospective, multicenter, nonblinded, phase IIIb clinical trial. • Participants: 401 adult patients with signs and symptoms of AECB. • Intervention: Patients randomly received a 5-day oral regimen of either moxifloxacin (400 mg once-daily) or azithromycin (500 mg on day 1, and 250 mg once daily for 4 days). • Outcome measures: Rate of clinical success at followup 14 to 21 days after completion of therapy. Patientreported responses to therapy (time to symptom relief and resumption of normal activities) were assessed by questionnaire. Drug-related adverse events were also assessed. • Results: Clinical resolution at 14 to 21 days was 85% for moxifloxacinand 81% for azithromycin-treated patients (95% confidence interval, –6.0% to 14.0%). Drugrelated adverse events reported in the moxifloxacin and azithromycin groups were 12% and 9%. Patients in the moxifloxacin group reported feeling better significantly faster than did patients in the azithromycin group (P = 0.0236). More moxifloxacin-treated patients (40%; 71 of 176) reported symptomatic relief by day 3 than did azithromycin-treated patients (27%; 45 of 165) (P = 0.012). More moxifloxacin-treated patients (36%; 58 of 163) reported a return to normal activities within 3 days of therapy than did azithromycin-treated patients (26%; 41 of 159). No significant differences were observed in average work time lost. • Conclusions: Short-course moxifloxacin was as effective and safe as azithromycin in the treatment of AECB. Patients treated with moxifloxacin reported faster symptom relief and returned to normal activities more rapidly. Acute exacerbation of chronic bronchitis (AECB) is a common respiratory condition associated with substantial patient morbidity. Approximately 50% of patients who experience acute exacerbations report at least 2 episodes per year [1,2]. More than 12 million outpatient physician visits are related to AECB. Twenty percent of patients with AECB will require hospitalization due to the development of pneumonia and/or respiratory insufficiency [1–3]. Most patients experiencing an exacerbation consult a primary care physician and are prescribed antibiotic therapy. Bacterial cultures generally are not performed due to the time, expense, and difficulty of obtaining uncontaminated bronchial sputum samples in the primary care setting. Although bacteriologic eradication is an important marker of overall antimicrobial efficacy, a quick return to work or other activities as reported by patients is also a clinically important outcome. The Moxifloxacin Therapeutic Circles program was initiated to provide a clinically relevant practice perspective on the treatment of AECB. This trial, which was conducted exclusively in the primary care setting, compared moxifloxacin and azithromycin for the treatment of AECB. Although clinical efficacy was the primary outcome of interest in this study, patient-reported outcomes were also assessed. The trial attempted to simulate actual clinical practice conditions; accordingly, bacteriologic assessments and follow-up cultures were not conducted, reflecting an empiric approach to treatment.
3
Standards for the Diagnosis and Care of Patients with Chronic Obstructive Pulmonary Disease
Bartolomé R. Celli, Gordon L. Snider, John E. Heffner et al. · 1995 · 3.5K citations
Medicine, Surgery, Exercise Testing +16
Acute infective exacerbations of chronic bronchitis
Peter Ball, Jessica Harris, D. Lowson et al. · QJM · 1995 · 203 citations
C. Andrew DeAbate, Chavaramplakic P. Mathew, John Harley Warner et al. · Respiratory Medicine · 2000 · 96 citations · Full text